• Radiation Therapy
      • Treatment Delivery
        • Elekta Unity Elekta Unity
        • Versa HD Versa HD
        • Elekta Harmony Elekta Harmony
        • Elekta Infinity Elekta Infinity
        • Elekta Synergy Elekta Synergy
      • Treatment Management
      • Quality Assurance
        • Machine QA
        • Patient QA
    • Stereotactic Radiosurgery
      • Delivery
        • Elekta Esprit Elekta Esprit
        • Leksell Gamma Knife Icon Leksell Gamma Knife Icon
        • Leksell Gamma Knife Perfexion Leksell Gamma Knife Perfexion
        • Versa HD Versa HD
      • Treatment Planning
        • Leksell Gamma Knife Lightning
        • Leksell GammaPlan
    • Oncology Software
      • Elekta ONE
        • Oncology care
        • Workflow management
        • Treatment applications
        • Real-world outcomes
        • Subscribe to Better
        • Elekta Axis Cloud
        • Interoperability
        • Professional Services
    • Brachytherapy
      • Delivery
        • Elekta Studio Elekta Studio
        • ImagingRing ImagingRing
        • Oncentra Brachy Oncentra Brachy
        • Venezia Venezia
        • Flexitron Flexitron
        • Geneva Geneva
      • Body Sites
        • Head and Neck
        • Bronchus and Oesophagus
        • Breast
        • Skin
        • Prostate
        • Rectum
        • Bladder
        • Gynecology
    • Neurosurgery
      • Delivery
        • Leksell Vantage Stereotactic System Leksell Vantage Stereotactic System
        • Leksell Stereotactic System Leksell Stereotactic System
    • Veterinary Radiation Therapy
    • Elekta Care
    • Elekta Care Support Services
    • Elekta Care 360
    • Elekta Care Learning
    • Elekta Care Community
    • Elekta Partner Community
    • MR-Linac Treatment
    • Brachytherapy Treatment
    • Gamma Knife Treatment
    • Radiation Therapy Treatment
    • Treatment Centers
    • Company
    • Partnering with Elekta
    • About us
      • About us
        • Board of Directors
        • Code of Conduct
        • Corporate Citizenship
        • Executive Management
        • Integrity Line
        • Programs
        • Sponsorship and Donation
        • Story
    • Sustainability
    • Corporate Governance
      • Corporate Governance
        • Shareholders’ meetings
          • Board of Directors
            • Executive Management
              • Auditors
              • Reports
          • Investors
            • Investors
              • Investment case
                • Outlook
                • The share
                  • Financials
                    • Funding
                      • Reports & presentations
                      • Press releases
                      • IR calendar
                      • IR contacts
                  • Newsroom
                    • Newsroom
                      • Press Releases
                      • FOCUS Magazine
                      • Events
                      • Image bank
                  • Careers at Elekta
                    • Jobs
                  • Reimbursement Support & Policy
                ENSV
                Login
                • Products
                  • Radiation Therapy
                    • Treatment Delivery
                      • Elekta Unity
                      • Versa HD
                      • Elekta Harmony
                      • Elekta Infinity
                      • Elekta Synergy
                    • Treatment Management
                    • Quality Assurance
                      • Machine QA
                      • Patient QA
                  • Stereotactic Radiosurgery
                    • Delivery
                      • Elekta Esprit
                      • Leksell Gamma Knife Icon
                      • Leksell Gamma Knife Perfexion
                    • Treatment Planning
                      • Leksell Gamma Knife Lightning
                      • Leksell GammaPlan
                    • Versa HD
                  • Oncology Software
                    • Elekta ONE
                      • Oncology care
                      • Workflow management
                      • Treatment applications
                      • Real-world outcomes
                      • Subscribe to Better
                      • Elekta Axis Cloud
                      • Interoperability
                      • Professional Services
                  • Brachytherapy
                    • Elekta Studio
                    • ImagingRing
                    • Venezia
                    • Flexitron
                    • Geneva
                    • Head and Neck
                    • Bronchus and Oesophagus
                    • Breast
                    • Skin
                    • Prostate
                    • Rectum
                    • Bladder
                    • Gynecology
                    • Oncentra Brachy
                  • Neurosurgery
                    • Leksell Vantage Stereotactic System
                    • Leksell Stereotactic System
                  • Veterinary Radiation Therapy
                • Services
                  • Elekta Care
                  • Elekta Care Support Services
                  • Elekta Care 360
                  • Elekta Care Learning
                  • Elekta Care Community
                  • Elekta Partner Community
                • Patients
                  • MR-Linac Treatment
                  • Brachytherapy Treatment
                  • Gamma Knife Treatment
                  • Radiation Therapy Treatment
                  • Treatment Centers
                • Company
                  • Partnering with Elekta
                  • About us
                    • Board of Directors
                    • Code of Conduct
                    • Corporate Citizenship
                    • Executive Management
                    • Integrity Line
                    • Programs
                    • Sponsorship and Donation
                    • Story
                  • Sustainability
                  • Corporate Governance
                    • Shareholders’ meetings
                      • Board of Directors
                        • Executive Management
                          • Auditors
                          • Reports
                        • Investors
                          • Investment case
                            • Outlook
                            • The share
                              • Financials
                                • Funding
                                  • Reports & presentations
                                  • Press releases
                                  • IR calendar
                                  • IR contacts
                                • Newsroom
                                  • Press Releases
                                  • FOCUS Magazine
                                  • Events
                                  • Image bank
                                • Careers at Elekta
                                  • Jobs
                                • Reimbursement Support & Policy
                              • Contact
                              • Medical Affairs
                              • Regulatory Affairs
                              • Suppliers
                                • About Elekta Procurement
                                • Sustainable Sourcing
                                • Performance Management
                                  • Production Part Approval Process
                                  • Supplier Escalation Form
                                  • Non Conformance Management
                                  • Supplier Performance Management
                                  • Obsolescence Management
                                • Compliance Management
                                • Invoicing Process
                                • Elekta T&C
                                • Documents & Training
                                • Our Global Presence
                              • Facebook logo
                              • LinkedIn logo
                              • Twitter logo
                              • Instagram icon
                              • YouTube play button

                              Year-end report, May–April 2022/23

                              May 25, 2023

                              Strong revenue growth and record cash flow

                              During the fourth quarter, the improved supply chain situation resulted in strong revenue growth, lower working capital and record level cash flow. The Cost-reduction Initiative supported EBIT margin improvement. Going forward we expect continued revenue growth and improved margins.

                              Gustaf Salford
                              President and CEO

                              Fourth quarter
                              • Gross order intake increased by 8 percent to SEK 6,359 M (5,897), corresponding to a 0 percent increase in constant exchange rates
                              • Net sales increased by 21 percent to SEK 5,125 M (4,239), corresponding to a 10 percent increase in constant exchange rates
                              • Adjusted gross margin amounted to 37.8 percent (37.0)
                              • Adjusted EBIT amounted to SEK 832 M (570), corresponding to an adjusted EBIT margin of 16.2 percent (13.4)
                              • Earnings per share was SEK 1.43 (1.09) before dilution and SEK 1.43 (1.09) after dilution
                              • Adjusted earnings per share was SEK 1.53 (1.09) before dilution and SEK 1.53 (1.09) after dilution
                              • Cash flow after continuous investments amounted to SEK 1,574 M (623)

                              Full year
                              • Gross order intake increased by 10 percent to SEK 20,143 M (18,364), corresponding to a 1 percent decrease in constant exchange rates
                              • Net sales increased by 16 percent to SEK 16,869 M (14,548), corresponding to a 4 percent increase in constant exchange rates
                              • Adjusted gross margin amounted to 38.1 percent (37.4)
                              • Adjusted EBIT amounted to SEK 1,743 M (1,643), corresponding to an adjusted EBIT margin of 10.3 percent (11.3)
                              • Earnings per share was SEK 2.47 (3.02) before dilution and SEK 2.47 (3.02) after dilution
                              • Adjusted earnings per share was SEK 3.11 (3.02) before dilution and SEK 3.10 (3.02) after dilution
                              • Cash flow after continuous investments amounted to SEK 400 M (450)

                              Significant events after the quarter
                              • The Board of Directors proposes a dividend of SEK 2.40 (2.40) per share (paid in two installments) for 2022/23
                               
                              New outlook from 2022/23 to 2024/25
                              • Net sales CAGR of above 7 percent
                              • EBIT margin expansion

                              Group summaryQ4Full-year
                              SEK M2022/232021/22Δ2022/232021/22Δ
                              Gross order intake6,3595,8970%120,14318,364-1%1
                              Net sales5,1254,23910%116,86914,5484%1
                              Adjusted gross margin 237.8%37.0%0.8 ppts 38.1%37.4%0.7 ppts 
                              Adjusted EBIT 383257046%1,7431,6436%
                              Adjusted EBIT margin 316,2%13,4%2.8 ppts10,3%11,3%-1 ppts
                              Gross margin37.7%37.0%0.6 ppts37.6%37.4%0.3 ppts
                              EBIT78457038%1,4311,643-13%
                              EBIT margin15,3%13,4%1.9 ppts8,5%11,3%-2.8 ppts
                              Cash flow after continous investments1,574623153%400450-11%
                              Adjusted earnings per share before/after dilution, SEK4 1.53 / 1.531.09 / 1.0941%3.11 / 3.103.02 / 3.023%
                              Earnings per share before/after dilution, SEK 1.43 / 1.431.09 / 1.0931%2.47 / 2.473.02 / 3.02-18%

                              1 Compared to last fiscal year based on constant exchange rates.
                              2 Adjusted gross margin = Gross margin excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 26.
                              3 Adjusted EBIT = Operating income (EBIT) excluding items affecting comparability attributable to the Cost-reduction Initiative within the Resilience and Excellence Program, see page 27.
                              4 Adjusted earnings per share = Net income attributable to Parent Company shareholders, excluding items affecting comparability attributable to the Cost-reduction Initiative, in relation to the weighted average number of shares (excluding treasury shares), see page 27.

                              # # #
                               
                              For further information, please contact:
                              Tobias Hägglöv, CFO
                              Tel: +46 76 107 4799, e-mail: tobias.hagglov@elekta.com  
                              Time zone: CET: Central European Time

                              Cecilia Ketels, Head of Investor Relations
                              Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
                              Time zone: CET: Central European Time

                              About Elekta
                              As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.

                              This information is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-25 07:30 CEST.

                              Attachments


                              Elekta Q4 Report 22 23

                              Downloads

                              • Elekta Q4 Report 22 23
                              • Products
                                • Radiation Therapy
                                • Stereotactic Radiosurgery
                                • Oncology Software
                                • Brachytherapy
                                • Neurosurgery
                                • Veterinary Radiation Therapy
                              • Services
                                • Elekta Care
                                • Elekta Care Support Services
                                • Elekta Care 360
                                • Elekta Care Learning
                                • Elekta Care Community
                                • Elekta Partner Community
                              • Patients
                                • MR-Linac Treatment
                                • Brachytherapy Treatment
                                • Gamma Knife Treatment
                                • Radiation Therapy Treatment
                                • Treatment Centers
                              • Company
                                • Partnering with Elekta
                                • About us
                                • Sustainability
                                • Corporate Governance
                                • Investors
                                • Newsroom
                                • Careers at Elekta
                                • Country and regional pages
                                • Digital Product Security
                                • Offices
                              • Facebook logo
                              • LinkedIn logo
                              • Twitter logo
                              • Instagram icon
                              • YouTube play button
                              • ©2023 Elekta
                              • Legal notices
                              • Privacy policy
                              • Cookies
                              • Subscription center

                              Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.

                              © 2023 Elekta

                              • Legal notices
                              • Privacy policy
                              • Cookies
                              • Subscription center

                              Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.